Zimmer Biomet Holdings Inc (N:ZBH)

Business Focus: Medical Equipment, Supplies & Distribution

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: 345 E Main St
WARSAW IN 46580-2746
Tel: 1-574-3719449
Website: www.zimmerbiomet.com
IR: See website
<
Key People
Bryan C. Hanson
President, Chief Executive Officer, Director
Daniel E. Williamson
Group President, Joint Reconstruction
Daniel P. Florin
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Robert D. Delps
President, Americas
Sang Yi
President, Asia Pacific
Chad F. Phipps
Senior Vice President, General Counsel, Secretary
Coleman N. Lannum
Senior Vice President - Investor Relations
Derek M. Davis
Vice President of Investor Relations
Aure Bruneau
Group President, Spine, CMF, Thoracic and Surgery Assisting Technology
David A. Nolan
Group President of Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle and Bone Healing
   
Business Overview
Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.
Financial Overview
For the fiscal year ended 31 December 2018, Zimmer Biomet Holdings Inc revenues increased 1% to $7.93B. Net loss before extraordinary items totaled $408.1M vs. income of $541.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Goodwill and intangible asset impairment increase from $304.7M to $979.7M (expense), Selling.
Employees: 18,200 as of Dec 31, 2017
Reporting Currency: U.S. Dollars
Enterprise value: $33,618M as of Dec 31, 2018
Annual revenue (TTM): $7,933M as of Dec 31, 2018
EBITDA (TTM): $2,325M as of Dec 31, 2018
Net annual income (TTM): -$408.10M as of Dec 31, 2018
Free cash flow (TTM): $1,113M as of Dec 31, 2018
Net Debt Last Fiscal Year: $8,396M as of Dec 31, 2018
Shares outstanding: 203,976,311 as of Dec 31, 2018
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization